The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
An article from
The FDA, through a new approval, gave Viridian’s drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.
Published June 30, 2026
Viridian's drug Lumvoa could pose a competitive threat to Amgen's Tepezza in the thyroid eye disease market.
Getty Images
FDA approves Viridian's Lumvoa for thyroid eye disease, launching competition with Amgen's $1.9B Tepezza on efficacy and infusion…
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient…
Viridian Therapeutics has scored an FDA
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a |…
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease,…
